Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bortezomib + Tabalumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|Tabalumab||LY2127399||Tabalumab (LY2127399) is a monoclonal antibody that neutralizes B-cell activating factor (BAFF), resulting in decreased development of osteoclasts and thus, potential antitumor activity (PMID: 27287072, PMID: 28005265).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||Bortezomib + Tabalumab||Phase I||Actionable||In a Phase I trial, 42% (20/46) of patients with multiple myeloma demonstrated a partial response, including 3 with a complete response and 2 with a very good partial response, when treated with a combination of Tabalumab and Velcade (bortezomib) (PMID: 27287072).||27287072|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|